Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SGMO

SGMO - Sangamo Therapeutics Inc Stock Price, Fair Value and News

$0.36-0.02 (-5.26%)
Market Closed

3/100

SGMO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

3/100

SGMO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.3

Target 3M

$0.34

Target 6M

$0.32

SGMO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SGMO Price Action

Last 7 days

-5.3%

Last 30 days

-12.2%

Last 90 days

-36.8%

Trailing 12 Months

-68.1%

SGMO RSI Chart

SGMO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SGMO Valuation

Market Cap

121.1M

Price/Earnings (Trailing)

-1.11

Price/Sales (Trailing)

3.68

EV/EBITDA

-0.87

Price/Free Cashflow

-2.03

SGMO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.3

Target 3M

$0.34

Target 6M

$0.32

SGMO Fundamentals

SGMO Revenue

Revenue (TTM)

32.9M

Rev. Growth (Yr)

-98.82%

Rev. Growth (Qtr)

-96.83%

SGMO Earnings

Earnings (TTM)

-108.9M

Earnings Growth (Yr)

-427.31%

Earnings Growth (Qtr)

-74.77%

SGMO Profitability

EBT Margin

-332.63%

Return on Equity

-1.7K%

Return on Assets

-122.86%

Free Cashflow Yield

-49.37%

SGMO Investor Care

Shares Dilution (1Y)

61.27%

Diluted EPS (TTM)

-0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202569.8M81.7M32.9M0
2024146.6M117.0M87.4M57.8M
2023241.0M218.5M201.4M176.2M
2022112.7M114.2M112.1M111.3M
2021131.4M137.7M108.5M110.7M
2020107.4M111.4M147.2M118.2M
201979.9M76.0M74.4M102.4M
201845.8M58.9M70.7M84.5M
201718.9M23.4M32.4M36.6M
201630.0M25.3M19.6M19.4M
201551.2M49.2M45.4M39.5M
201427.6M31.1M37.8M45.9M
201323.0M25.4M26.2M24.1M
201211.4M14.4M17.5M21.7M
201116.4M11.3M10.3M10.3M
201000020.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Sangamo Therapeutics Inc

SGMO
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
 CEO
 WEBSITEsangamo.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES478

Sangamo Therapeutics Inc Frequently Asked Questions

SGMO is the stock ticker symbol of Sangamo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sangamo Therapeutics Inc is 121.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SGMO's fair value in chart for subscribers.

The fair value guage provides a quick view whether SGMO is over valued or under valued. Whether Sangamo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sangamo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGMO.

As of Wed Jan 28 2026, SGMO's PE ratio (Price to Earnings) is -1.11 and Price to Sales (PS) ratio is 3.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGMO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Sangamo Therapeutics Inc has provided -0.246 (multiply by 100 for percentage) rate of return.